Progressive Myoclonic Epilepsies

This is a group of serious brain disorders. They cause seizures, especially muscle jerks (myoclonus). Some types also cause problems with balance (ataxia) and can lead to a slow decline in mental abilities. These conditions can run in families.

Condition

What people with Progressive Myoclonic Epilepsies report

Every report comes from a Lived member, sent anonymously.

Have you tried Valproic Acid for Progressive Myoclonic Epilepsies?

NameHow it went

About Progressive Myoclonic Epilepsies

What It Is

Progressive myoclonic epilepsies (also called progressive myoclonus epilepsies, or PME) are a group of rare, mostly inherited brain disorders. They combine three main problems: myoclonus (sudden, brief muscle jerks), seizures and ataxia (difficulty with balance and coordination). Unlike most forms of epilepsy, the underlying disease itself progresses, so these problems usually grow over months to years. Symptoms often begin in later childhood or adolescence. Myoclonus is the defining feature and usually the most disabling one. The jerks are often triggered or made worse by movement, light, sound or touch, so reaching for a cup, writing or starting to walk can set off a burst of jerks. Many people also have tonic-clonic seizures (convulsions with loss of consciousness). Depending on the type, there may also be decline in thinking and memory, vision loss, or changes in mood and behavior. PME is an umbrella term rather than a single disease. Almost fifty genetic causes are known. The most common is Unverricht-Lundborg disease. Others include Lafora disease, the neuronal ceroid lipofuscinoses (often called Batten disease), MERRF (myoclonic epilepsy with ragged red fibers, a mitochondrial disorder) and sialidosis. The specific type matters, because it shapes the outlook and, in a few cases, the treatment.

Causes & Risk Factors

Nearly all forms of PME are caused by changes in a single gene, and each gene causes a distinct disease. These are not conditions a person brings on through anything they or their parents did. Most forms are autosomal recessive. A child is affected only when they inherit a non-working copy of the same gene from each parent. The parents are usually healthy carriers, so the family history often shows nothing unusual, or only an affected brother or sister. The chance is higher when parents are related by blood, and some forms are more common in particular regions because of shared ancestry; Unverricht-Lundborg disease, for example, is most frequent in Finland. A few forms are inherited differently. MERRF comes from changes in mitochondrial DNA, the small separate set of genes that powers cells. One form, linked to a gene called KCNC1 that helps control nerve signaling, usually arises from a new genetic change in the child rather than one passed down. The gene involved determines what goes wrong in brain cells; in Lafora disease, for example, abnormal clumps of a sugar-storage molecule build up inside them.

How It's Diagnosed

Doctors consider PME when myoclonus does not respond well to medication, especially alongside worsening coordination, seizures or changes in thinking. A neurologist takes a detailed history, examines balance, movement and vision, and asks about relatives with similar symptoms and whether the parents are related. Some findings point toward particular types: a cherry-red spot at the back of the eye suggests sialidosis, protein in the urine suggests action myoclonus-renal failure syndrome (a type that also affects the kidneys), and hearing loss or muscle weakness can suggest MERRF. An EEG (electroencephalogram), which records the brain's electrical activity, is done for everyone. It often shows generalized seizure discharges and a sensitivity to slow flashing lights, and over time the background activity may slow. A brain MRI (magnetic resonance imaging) scan is usually normal or shows only general shrinkage, so it mainly helps rule out other causes. Genetic testing is now the first-line test, and it identifies the cause in about 80% of people with PME. Broad tests such as gene panels, exome or genome sequencing are preferred over testing one gene at a time. One limitation matters in practice: the most common change behind Unverricht-Lundborg disease is a repeated stretch of DNA that standard panels and exome tests often miss, so it may need a specific test. Because most forms are recessive, finding only one changed copy of a gene usually means a person is a carrier, not that the cause has been found. When results are inconclusive, the data can be reanalyzed later as knowledge grows, and skin or muscle biopsies are sometimes used.

Treatment Options

For most types of PME, no treatment slows the disease itself. Treatment aims to reduce seizures and myoclonus, and most people need a combination of antiseizure medicines. Valproate (Depakote) is often the starting point. Benzodiazepines such as clonazepam (Klonopin) are commonly added to calm myoclonus, and levetiracetam (Keppra), topiramate, zonisamide and perampanel (Fycompa) have also been reported to help. Tonic-clonic seizures usually respond better than myoclonus, which often persists even with several medicines. Side effects shape the choice: in one small study of perampanel, half of the people treated gained weight and half had mood or behavior changes. Choosing medicines for PME differs from treating most epilepsies. Several common seizure medicines, including phenytoin, carbamazepine, oxcarbazepine, gabapentin and pregabalin, can worsen myoclonus, so they are generally avoided. Valproate also needs care: it must not be used in mitochondrial disease caused by changes in the POLG gene and is used only with caution in other mitochondrial disorders such as MERRF, because of a risk of liver failure, and it can cause serious birth defects, which matters for anyone who could become pregnant. One type has a treatment that targets the disease. For CLN2 disease, a form of Batten disease, the enzyme replacement cerliponase alfa (Brineura) is infused directly into the fluid-filled spaces of the brain. It is approved to slow the loss of walking in children, and treated children lost motor and language skills more slowly than in records of untreated children from before the treatment existed. It does not restore lost abilities, which is one reason early diagnosis matters. Other approaches have weaker support. Special diets such as the ketogenic diet, and devices such as vagus nerve stimulation or deep brain stimulation, have helped some people in small case reports with mixed results. Metformin, a diabetes medicine, looked promising for Lafora disease in animals, but limited human data have not shown a meaningful benefit. Gene-based treatments are being studied but are not yet available outside research.

What to Expect

The course depends heavily on the specific type, so a confirmed genetic diagnosis is the best guide to what lies ahead. Across types, myoclonus tends to cause the most day-to-day difficulty, affecting walking, eating, writing and other tasks that need steady movement. Falls and injuries such as broken ankles are common, and many people eventually need help with mobility. Unverricht-Lundborg disease usually starts around age 12 or 13. Myoclonus worsens over several years and then tends to level off in middle adulthood, while tonic-clonic seizures often become less frequent. Thinking is relatively preserved, although processing speed and planning can be affected. Many people keep a degree of independence for years, though average life expectancy is shortened. Lafora disease is among the most severe forms. It usually begins between ages 8 and 19, often with seizures that cause visual symptoms, and leads to a rapid decline in thinking, vision and movement. Recent data suggest a median survival of about 11 years after symptoms begin, with later onset linked to a slower course. Other types fall at different points: the Batten diseases usually begin in early childhood with seizures, delayed speech or vision loss, depending on the form, while the KCNC1-related form causes severe myoclonus but largely spares thinking. Depression and other mental health problems are common, particularly in Unverricht-Lundborg disease, where they include a raised risk of suicidal behavior, and deserve the same attention as seizures. Care usually involves regular visits with a neurologist experienced in epilepsy, with medicines adjusted as the disease changes. Genetic counseling helps families understand the chance that siblings or future children are affected, and contact with specialist centers can open access to research studies.

When to Seek Help

Arrange an evaluation with a neurologist when muscle jerks keep returning or worsening, especially when they come with seizures, clumsiness or a decline in school or work performance. If PME is suspected, ask whether genetic testing is appropriate. Contact the care team promptly if jerks or seizures clearly increase, particularly after starting a new medicine or changing a dose, or if new problems such as frequent falls, vision changes or persistent low mood appear. Thoughts of suicide or self-harm need urgent help the same day; call or text 988 (the Suicide and Crisis Lifeline) if someone may act on them. Call 911 if a seizure lasts longer than 5 minutes, or if seizures follow one another without the person waking up in between.

Questions to Ask Your Doctor

  1. 1.Which type of progressive myoclonic epilepsy is this, and if genetic testing was negative, could the repeated DNA change behind Unverricht-Lundborg disease, or another hard-to-detect change, have been missed?
  2. 2.Which seizure medicines are most likely to help this type, and which should be avoided because they could worsen myoclonus?
  3. 3.What course is typical for this type, and how will we track changes in movement, thinking, vision and mood?
  4. 4.What does this diagnosis mean for brothers, sisters or future children, and should relatives see a genetic counselor?
  5. 5.Are there clinical trials or specialist centers we should know about for this type?

Last reviewed • Oct 2026

Educational content, not medical advice.